Literature DB >> 35619833

A Case of Recurrent Respiratory Papillomatosis With Lung Involvement and Malignant Transformation.

Alejandra Valdivia Padilla1, Eduardo Tellez-Garcia1, Horiana Grosu2.   

Abstract

Recurrent respiratory papillomatosis is a rare and complex progression of the disease due to the human papillomavirus (HPV). In this case report, we present the findings of a 53-year-old male who was diagnosed with obstructing respiratory papillomatosis of the trachea and underwent several procedures until the disease progressed to squamous cell carcinoma. Our objective with this case report is to contribute to a broader understanding of this disease by reporting a clinical case.
Copyright © 2022, Valdivia Padilla et al.

Entities:  

Keywords:  bronchoscopy; human papillomavirus (hpv); papillomas; recurrent respiratory papillomatosis; tracheoesophageal fistula

Year:  2022        PMID: 35619833      PMCID: PMC9126428          DOI: 10.7759/cureus.24370

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Recurrent respiratory papillomatosis (RRP) is a challenging disease to treat. It is the result of infection by human papillomavirus (HPV) [1,2], most commonly involving the subtypes HPV-6 and HPV-11 [3-5]. Although any part of the aerodigestive tract can be affected, the most common location of papillomas is the larynx [1,2]. The clinical course varies greatly, with some cases resolving spontaneously and others recurring multiple times and requiring several surgical procedures [2,6]. The most common symptoms are hoarseness, dyspnea, cough, and dysphagia, among others [7]. Papillomas are usually benign, but dysplasia and malignant transformation sometimes can be seen [2,8]. Pulmonary lesions tend to be unusual and represent less than 1% of all lung neoplasms [2,9]; however, when the progression of the disease becomes severe, these lesions could cause damage to the pulmonary parenchyma [2,9].

Case presentation

A 53-year-old male was diagnosed with obstructing RRP of the trachea in 2018 and underwent repeated bronchoscopic debulking procedures. These were complicated by a tracheoesophageal fistula, which required several surgical interventions. Thereafter, the papillomas of the trachea recurred, and the patient had repeated bronchoscopic removals (Figure 1A). A computed tomography (CT) showed bilateral small lung nodules (Figure 1B). On subsequent CT, nodules progressed to cavitary nodules (Figure 1C). Biopsy of the cavitary nodules showed focal atypical squamous proliferation. Given the progression of the cavitary nodules (Figure 1D), a repeat biopsy was performed and squamous cell carcinoma was reported. In addition to surgery, the patient started therapy with carboplatin and pembrolizumab. Overall, the patient had a total of 14 therapeutic bronchoscopies before developing pulmonary disease that progressed to squamous cell carcinoma. Unfortunately, the patient’s cancer progressed further, and he was considered for hospice.
Figure 1

Papillomas in the trachea (A).

CT scans showing bilateral small lung nodules (B), progression to cavitary nodules (C), and progression to squamous cell carcinoma (confirmed by biopsy) (D).

Papillomas in the trachea (A).

CT scans showing bilateral small lung nodules (B), progression to cavitary nodules (C), and progression to squamous cell carcinoma (confirmed by biopsy) (D).

Discussion

Though there is no cure for RRP [1,2], surgery remains the mainstay therapy [1,8], while the recurrence rate remains a challenge [2,10]. According to literature after four surgical procedures in approximately 12 months [1,2,8], there is a need to establish adjunctive therapies [8]. In cases where the patency of the airway is severely compromised, tracheotomy is often necessary [2,8]. HPV vaccination plays a key role in RRP prevention [1,11,12], as studies have shown a decrease in incidence and prevalence, it also has demonstrated a potential therapeutic use for the vaccine [11-13]. Immunotherapy also has a potential role in managing RRP, owing to the pathophysiology of RRP and the new evidence that HPV infection causes an immune dysregulation, representing a promising line of research [1,11,12].

Conclusions

Clinicians should be aware of the possible complications of HPV in order to establish complementary therapies in patients susceptible to developing RRP. Furthermore, the vaccine continues to be the main preventive measure to avoid this disease. However, as with immunotherapy, more research is needed to determine the extent to which it can be used as a therapeutic measure.
  13 in total

1.  Multi-Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis.

Authors:  Hiroumi Matsuzaki; Kiyoshi Makiyama; Ryoji Hirai; Hirotaka Suzuki; Ryohei Asai; Takeshi Oshima
Journal:  Laryngoscope       Date:  2019-04-08       Impact factor: 3.325

2.  Pharmacotherapy for recurrent respiratory papillomatosis (RRP): a treatment update.

Authors:  Adam J Donne; Andy Kinshuck
Journal:  Expert Opin Pharmacother       Date:  2021-07-05       Impact factor: 3.889

Review 3.  Recurrent respiratory papillomatosis: A state-of-the-art review.

Authors:  Helena Ribeiro Fortes; Felipe Mussi von Ranke; Dante Luiz Escuissato; Cesar Augusto Araujo Neto; Gláucia Zanetti; Bruno Hochhegger; Carolina Althoff Souza; Edson Marchiori
Journal:  Respir Med       Date:  2017-04-01       Impact factor: 3.415

4.  Human papillomavirus 6, 11, and 16 in laryngeal papillomas.

Authors:  P Dickens; G Srivastava; S L Loke; S Larkin
Journal:  J Pathol       Date:  1991-11       Impact factor: 7.996

Review 5.  Recurrent respiratory papillomatosis.

Authors:  R A Tasca; R W Clarke
Journal:  Arch Dis Child       Date:  2006-08       Impact factor: 3.791

Review 6.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

7.  Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers.

Authors:  L Gissmann; L Wolnik; H Ikenberg; U Koldovsky; H G Schnürch; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

8.  Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis.

Authors:  Farrel J Buchinsky; William L Valentino; Nicole Ruszkay; Evan Powell; Craig S Derkay; Riaz Y Seedat; Virgilijus Uloza; Frederik G Dikkers; David E Tunkel; Sukgi S Choi; Anthony J Mortelliti; Paolo Campisi; Juan C Ospina; Adam J Donne; Robert T Sataloff; Stephen F Conley; John E McClay; Ellen M Friedman; Lisa Elden; Dale A Tylor; Clark A Rosen; Libby J Smith; Graeme J Copley; David E Karas; John M Schweinfurth; Charles M Myer; Brian J Wiatrak; Joseph E Dohar; Steven E Sobol; Robert W Bastian; Richard J H Smith; Marshall E Smith; Abebe M Wassie; James C Post; Garth D Ehrlich
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

Review 9.  Recurrent respiratory papillomatosis: A 2020 perspective.

Authors:  Jacob J Benedict; Craig S Derkay
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.